Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101

ERASE

Evaluation of Response Adapted Stereotactic ablative body radiotherapy (SABR) in advanced mElanoma receiving immunotherapy (ERASE part 1: pilot trial)

Open for recruitment

Trial summary

The ERASE study aims to develop a method for using Stereotactic Ablative Radiation Therapy (SABR) that accounts for both the anatomy (the shape and position of the cancer) and the biological response to immunotherapy and demonstrate that this approach is effective in treating metastatic melanoma.

Trial details

Short title

ERASE

Diagnosis

Skin cancer – melanoma

Type of treatment

Radiation Oncology

Phase

N/A

Locations

Investigators

Principal Investigators

Who can participate

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.